PF-Atlas › Treatments › Mocetinostat

Mocetinostat

Epigenetically unlocks fibroblasts from myofibroblast state

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Mechanism class
Epigenetically unlocks fibroblasts from myofibroblast state
Timeline
2-4 years
Risk profile
Medium
Developer
Multiple
Key researchers
Multiple

Overview

HDAC activity locks fibroblasts in activated state. Inhibition allows reversal to quiescent phenotype.

How Mocetinostat fits into IPF treatment

Mocetinostat is classified as Level 2 (Phase II) at the Phase II stage. Explore how it compares to other options and where it sits in the development pipeline:

Mocetinostat drug profileEpigenetically unlocks fibroblasts from myofibroblast stateClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Mocetinostat for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.